Lyell Immunopharma (NASDAQ: LYEL) net income
Lyell Immunopharma reported a net loss of $274.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $343.0m. Earnings per share were −$16.06.
Lyell Immunopharma's best year of the last 6 was fiscal 2022. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$274.4m | — | −762,355.6% | −$16.06 |
| 2024 | −$343.0m | — | −562,285.2% | −$1.31 |
| 2023 | −$234.6m | — | −180,486.2% | −$0.93 |
| 2022 | −$183.1m | — | −216.2% | −$0.74 |
| 2021 | −$250.2m | — | −2,349.5% | −$1.84 |
| 2020 | −$204.5m | — | −2,636.3% | −$15.69 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Lyell Immunopharma net income compared with its sector
By net income for its latest fiscal year, Lyell Immunopharma ranks 440th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Lyell Immunopharma, −762,355.6%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 438th | Nurix Therapeutics | −$264.5m | −314.9% |
| 439th | Ocular Therapeutix | −$265.9m | −511.9% |
| 440th | Lyell Immunopharma | −$274.4m | −762,355.6% |
| 441st | Relay Therapeutics | −$276.5m | −1,800.6% |
| 442nd | Kura Oncology | −$278.7m | −412.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Lyell Immunopharma
- How much did Lyell Immunopharma earn in fiscal 2025?
- Lyell Immunopharma reported a net loss of $274.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $343.0m.
- What are the earnings per share of Lyell Immunopharma?
- They were −$16.06 in fiscal 2025, compared with −$1.31 in fiscal 2024.
- Where does Lyell Immunopharma rank in its sector by net income?
- It ranks 440th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Lyell Immunopharma come from?
- From the annual report (Form 10-K) that Lyell Immunopharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Lyell Immunopharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Lyell Immunopharma: the Lyell Immunopharma page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.